Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xalacom vs Unfixed Latanoprost and Timolol in Glaucoma
NCT00219596Phase 3Completed
- Sponsor
- Viatris
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Viatris. Primary endpoint: Mean change from baseline to week 8 in diurnal intraocular pressure. Started Jun 2005; status: completed.
02
Drugs
timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00219596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219596.